Skip to main content
Addgene

AAV-GfaABC1D-Cre-4x6T
(Plasmid #196410)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 196410 Standard format: Plasmid sent in bacteria as agar stab 1 $85
AAV5 196410-AAV5 Virus (100 µL at titer ≥ 7 × 10¹² vg/mL) and Plasmid. $405

Backbone

  • Vector backbone
    pAAV-MCS
  • Backbone manufacturer
    Stratagene
  • Backbone size w/o insert (bp) 3406
  • Total vector size (bp) 5893
  • Modifications to backbone
    The GfaABC1D promoter and the 4x6T miRNA targeting cassette were added to confer astrocyte specificity.
  • Vector type
    Mammalian Expression, AAV ; Astrocyte-selective

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    Cre
  • Alt name
    Cre recombinase
  • Insert Size (bp)
    1032
  • Promoter GfaABC1D

Cloning Information

  • Cloning method Gibson Cloning
  • 5′ sequencing primer tagcccactccttcataaag
  • 3′ sequencing primer ttattaggacaaggctggtg
  • (Common Sequencing Primers)

Resource Information

  • Supplemental Documents
  • A portion of this plasmid was derived from a plasmid made by
    AAV-GfaABC1D-Cre-4x6T was created using AAV pmSyn1-EBFP-Cre (Addgene 51507) provided by Hongkui Zeng.
  • Article Citing this Plasmid

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Information for AAV5 (Catalog # 196410-AAV5) ( Back to top)

Purpose

Ready-to-use AAV5 particles produced from AAV-GfaABC1D-Cre-4x6T (#196410). In addition to the viral particles, you will also receive purified AAV-GfaABC1D-Cre-4x6T plasmid DNA.

GfaABC1D driven expression of Cre recombinase in astrocytes. These AAV preparations are suitable purity for injection into animals.

Delivery

  • Volume 100 µL
  • Titer ≥ 7 × 10¹² vg/mL
  • Pricing $375 USD for preparation of 100 µL virus + $30 USD for plasmid.
  • Storage Store at -80℃. Thaw just before use and keep on ice.
  • Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.

Viral Production & Use

  • Packaging Plasmids encode adenoviral helper sequences and AAV rep gene, AAV5 cap gene
  • Buffer PBS + 0.001% Poloxamer 188 + 200 mM NaCl
  • Serotype AAV5
  • Purification Iodixanol gradient ultracentrifugation

Biosafety

Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide

Terms and Licenses

Viral Quality Control

Quality Control:
  • Addgene ensures high quality viral vectors by optimizing and standardizing production protocols and performing rigorous quality control (QC) (see a list of our QC assays). The specific QC assays performed varies for each viral lot. To learn which specific QC assays were performed on your lot, please contact us.
  • Titer: the exact titer of your sample will be reported on the tube. The titer you see listed on this page is the guaranteed minimum titer. See how titers are measured.

Visit our viral production page for more information.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    AAV-GfaABC1D-Cre-4x6T was a gift from Stanley Thomas Carmichael (Addgene plasmid # 196410 ; http://n2t.net/addgene:196410 ; RRID:Addgene_196410) For viral preps, please replace (Addgene plasmid # 196410) in the above sentence with: (Addgene viral prep # 196410-AAV5)
  • For your References section:

    A toolbox of astrocyte-specific, serotype-independent adeno-associated viral vectors using microRNA targeting sequences. Gleichman AJ, Kawaguchi R, Sofroniew MV, Carmichael ST. Nat Commun. 2023 Nov 16;14(1):7426. doi: 10.1038/s41467-023-42746-w. 10.1038/s41467-023-42746-w PubMed 37973910